Shenzhen Neptunus Bioengineering plans to acquire a 70% stake in a pharmaceutical company based in Hunan, China.

The company expects the acquisition to cost them up to $29.11m.

Korea Value Asset Management has acquired a 5% stake in biotech company ATGen.

“Catalent plans to acquire Accucaps Industries to expand its over the counter (OTC) and prescription pharmaceutical softgel capabilities.”

The 5% stake represents 0.56m shares of the target company.

Catalent plans to acquire Accucaps Industries to expand its over the counter (OTC) and prescription pharmaceutical softgel capabilities.

Pursuant to the acquisition, Accucaps’ employees will join Calatent’s global network of softgel technologies and its blistering, bottling and packaging facilities will be included into Catalent’s softgel development and manufacturing units.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The acquisition enables Catalent to increase its production by the addition of new products.